Microtech Achieves Major Milestone in Cardiac Technology
Microtech, a wholly owned subsidiary of Medinol, is excited to share significant advancements in cardiac care technology with the recent U.S. implantations of its state-of-the-art atrial-pressure microsensors. These pioneering implantations represent a monumental step in enhancing how clinicians can monitor patients' cardiovascular health and optimize their treatments effectively.
Innovative Atrial-Pressure Microsensor Features
The atrial-pressure microsensor boasts unique features that set it apart from conventional devices. Its compact design, combined with a passive operational mode, eliminates the need for electronics or antennas, enabling effective signal transmission via ultrasound. This innovation allows the Microtech microsensor to function independently or be integrated with existing medical devices like Left Ventricular Assist Devices (LVADs), transforming them into sophisticated combination therapeutic-diagnostic systems.
Successful Surgical Procedures and Initial Implants
Recently, two atrial microsensors were implanted at New York-Presbyterian/Columbia University Irving Medical Center, under the skilled hands of Dr. Koji Takeda. This remarkable procedure took about five minutes and required only minimal alterations to the standard LVAD implantation method. This success adds to the five microsensors already implanted in other locations, showcasing the technology's versatility and ease of use.
Enhancing Patient Care with Advanced Monitoring
Dr. Nir Uriel, a distinguished expert in advanced heart failure and cardiac transplantation at NewYork-Presbyterian, highlighted the importance of the microsensor. He believes the ability to monitor both left and right-sided cardiac pressures non-invasively will significantly advance patient care. This innovation shifts the focus from simply addressing symptoms to employing parameter-based therapies, helping clinicians make more informed decisions.
The Future of Cardiac Monitoring
The Microtech First-In-Human (FIH) study aims to enroll approximately 15 patients across multiple locations. Yoram Richter, the CEO of Medinol, expressed excitement about the initial results and the sensors' performance. He noted the ongoing efforts to enhance this transformative technology by integrating microsensors into existing medical devices, thus fulfilling its vast potential.
About Medinol's Vision and Impact
Medinol is dedicated to reshaping how diseases are diagnosed and treated. The company focuses on creating advanced devices that improve patient care, including innovative stenting technologies and real-time physiological monitoring through implantable devices. By challenging traditional technologies and procedures, Medinol is committed to pioneering new solutions that expand healthcare accessibility for physicians worldwide.
Frequently Asked Questions
What is the Microtech atrial-pressure microsensor?
The Microtech atrial-pressure microsensor is a small, innovative device designed for non-invasive cardiac monitoring, offering enhanced data collection and integration with other medical devices.
How does the microsensor benefit patient care?
This technology enables continuous monitoring of cardiac pressures, leading to improved treatment protocols and personalized patient care based on real-time metrics.
What makes this microsensor unique?
Its entirely passive design allows for ease of implant and integration without the need for electronics, showcasing advanced ultrasound signal transmission capabilities.
How many patients are involved in the FIH study?
Approximately 15 patients are being enrolled in the FIH study to assess the microsensor's feasibility, usability, and accuracy.
Who is leading the implantation procedures?
Dr. Koji Takeda, a noted cardiac surgeon, plays a key role in performing these advanced implantation procedures, ensuring a successful integration of the technology.
